Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 29, 2009

Acrux’ Testosterone Treatment Triumphs in Phase III Study

  • Australian firm Acrux reports positive results from an international Phase III trial evaluating its topically applied testosterone replacement product, Axiron™, in 155 men with hypogonadism. The company aims to start formal partnering discussions for the product during October and projects filing an NDA by the end of 2009.

    The late-stage study confirmed that after four months of treatment, 84% of subjects using Axiron achieved average blood testosterone levels within the normal range. The company points out that this exceeds the 75% threshold expected by FDA. Trial data also showed that 76% of treated subjects achieved normal blood levels of testosterone after two weeks of treatment.

    Axiron is applied to the underarm using a no-touch applicator. In the Phase III trial, the optimum dose for 75% of patients was 60 mg testosterone per day, equivalent to a single application of Axiron to each armpit. Acrux says use of underarm deodorant in addition to Axiron had no adverse effects on its efficacy.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »